2Julian BA, Waldo FB, Rifai A , et al. IgA nephropathy, the most common glomerulonephritis worldwide. A neglected disease in the United States? [J].Am J Med,1988,84(1):129-30.
3Amitabyh P. Leflunomide: A review of its use in active rheumatoid arhtritis[J].Drugs, 1999, 58(6): 1137-64.
4Siemasko KF,Chong AS.Regulation of B cell function by the immunosuppressive agent leflunomide [J]. Clin Exp Imunol,1999,15(2):221-8.
5Hardinger KL, Wang CD, Schnitzler MA, et al.Prospective, pilot, open-label, short-term study of conversion to leflunomide reverses chronic renal allograft dysfunetion[J]. Am J Transplant,2002,2(9):867-71.
6Thoenes GH. Leflunomide inhibits experimental autoimmune tubulointerstitial nephritis in rats [J]. Int J Immunopharmacol, 1998, 11(2):921-9.
7Remer CF, Weisman MH, Wallace DJ. Benefits of leflunomide in systemic lupus erythematosus[J]. Lupus,2001, 10(7):480-3.
8Donadio J V. IgA nephropathy [J] .New Engl J Med,2002,347(10):347-8.
9Nolin. Management of IgA nephropathy:evidence-based recommendations[J].Kidney Int, 1999,70(1):s56-7.
10Dallin JJ. ACE inhibitor for IgA nephropathy: a meta analysis[J].J Am Soc Nephrol,1998,9(1):86-7.
5Li LS,Liu ZH.Epidem iologic data of renal diseases from a single unit in China:analysis based on 13,519 renal biopsies[J].Kidney Int,2004,66(3):920-923.
6Appel GB,Waldman M.The IgA nephropathy treatment dilemma[J].Kidney Int,2006,69(11):1939-1944.
7Barratt J,Feehally J.IgA nephropathy[J].J Am Soc Nephrol,2005,16(7):2088-2097.
8Sato M,Hotta O,Tomioka S,et al.Cohort study of advanced IgA nephropathy:efficacy and limitations of corticosteroids with tonsillectomy[J].Nephron Clin Pract,2003,93(4):c137-c145.
9Rasche FM,Schwarz A,Keller F.Tonsillectomy does not prevent a progressive course in IgA nephmpathy[J].Clin Nephrol,1999,51(3):147-152.
10Donadio JV,Bergstralh EJ,Gran e JP,etal.Proteinuria Patterns and their assoeiation with subsequent end-stage renal disease in IgA nephro Pathy[J].Nephrol Dial Trans Plant,2002,17(7):1197-1203.
